Zacks.com Spotlights Tactile Systems, Canadian Natural Resources, Arlo, and Celestica
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 20 2025
0mins
Should l Buy TCMD?
Source: NASDAQ.COM
Highlighted Stocks: The article discusses four efficient stocks to consider for investment: Tactile Systems Technology (TCMD), Canadian Natural Resources Ltd. (CNQ), Arlo Technologies (ARLO), and Celestica (CLS), all of which have shown strong earnings surprises.
Efficiency Ratios: Key efficiency ratios such as Receivables Turnover, Asset Utilization, Inventory Turnover, and Operating Margin are emphasized as important metrics for evaluating a company's potential to generate profits and manage resources effectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TCMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TCMD
Wall Street analysts forecast TCMD stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 25.880
Low
28.00
Averages
31.67
High
35.00
Current: 25.880
Low
28.00
Averages
31.67
High
35.00
About TCMD
Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tactile Systems Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Tactile Systems reported total revenue of $103.6 million in Q4 2025, reflecting a robust 21% increase that surpassed analyst expectations of $94 million, indicating strong performance in the medical device market.
- Profitability Improvement: The company's net income under GAAP rose by 9% to $10.6 million ($0.46 per share), showcasing sustained profitability and further bolstering investor confidence in the company's financial health.
- Strong Product Sales: Sales of airway clearance products surged by 66%, while sales and rentals of lymphedema treatment devices increased by 16%, demonstrating the effectiveness of the company's targeted strategies in niche markets.
- Optimistic Outlook: Management anticipates revenue growth of 8% to 11% in 2026, projecting figures between $357 million and $365 million, with non-GAAP EBITDA expected to range from $49 million to $51 million, highlighting the company's growth potential and market confidence moving forward.
See More
Wingstop Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Wingstop reported an adjusted EPS of $1.00 for Q4, surpassing analyst expectations of $0.84, indicating strong profitability and boosting market confidence in the company's future performance.
- Sales Miss: The quarterly sales of $175.694 million fell short of the analyst consensus estimate of $177.533 million, yet the overall performance reflects the company's resilience in a competitive fast-food market.
- Stock Surge: Following the earnings report, Wingstop's shares jumped 17.3% to $295.31 on Wednesday, signaling optimistic investor sentiment and potentially attracting more institutional interest in the stock.
- Positive Market Reaction: The broader U.S. stock market rose, with the Dow Jones index gaining around 250 points on Wednesday, and Wingstop's strong performance further fueled market optimism, reflecting investor confidence in the recovery of the restaurant sector.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, reflecting varying market perspectives on these companies' futures, which could influence investor decisions and market trends.
- Upgrades and Downgrades: Specific rating changes include both upgrades and downgrades for certain stocks, which may lead to short-term volatility in the respective stocks, prompting investors to pay close attention.
- Market Reaction Expectations: Analyst rating adjustments typically trigger immediate market reactions, as investors may reassess their portfolios based on this information, thereby impacting overall market sentiment.
- Further Information Access: For a complete view of all analyst rating changes, including upgrades and downgrades, it is recommended to visit our analyst ratings page to stay updated on the latest market dynamics and professional insights.
See More
Tactile Systems Acquires LymphaTech to Strengthen Market Position
- Strategic Acquisition: Tactile Systems announced the acquisition of LymphaTech for $6.8 million in cash, aimed at enhancing its market position in the medical technology sector, particularly in improving disease identification and treatment options for lymphedema patients, which is expected to bolster the company's competitive edge in a rapidly growing market.
- Strong Financial Performance: Tactile Systems reported fourth-quarter earnings of 46 cents per share, exceeding the market expectation of 44 cents, with sales jumping 21% to $103.59 million, significantly surpassing Wall Street's estimate of $93.80 million, indicating robust demand for its lymphedema and airway clearance product lines.
- Optimistic 2026 Outlook: The company forecasts fiscal 2026 sales between $357 million and $365 million, exceeding the consensus of $347.94 million, while expecting adjusted EBITDA in the range of $49 million to $51 million, reflecting strong growth potential ahead.
- Strong Stock Performance: Tactile Systems shares rose 23.35% to $34.60 in premarket trading on Wednesday, reaching a new 52-week high, indicating a positive market reaction to the acquisition news, while technical analysis shows strong short-term upward momentum.
See More
Pitney Bowes Q4 Earnings Beat Expectations, Shares Surge
- Earnings Surprise: Pitney Bowes reported an adjusted EPS of 45 cents for Q4, surpassing the analyst consensus of 38 cents, indicating strong profitability and boosting investor confidence.
- Sales Miss: The quarterly sales of $478 million fell short of the expected $486.68 million, highlighting some market demand challenges that could impact future revenue growth.
- Stock Surge: The company's shares jumped 7.9% to $11.05 in pre-market trading, reflecting optimistic market sentiment regarding its future prospects and potentially attracting more investor interest.
- Positive Guidance: Pitney Bowes issued FY26 adjusted EPS guidance with a midpoint above estimates, further strengthening market confidence in its long-term growth potential.
See More
Tactile Systems Reports Strong Q4 2025 Earnings and Strategic Acquisition
- Strong Financial Performance: Tactile Systems reported total revenue of $329.5 million for 2025, a 12% year-over-year increase, with Q4 revenue reaching $103.6 million, reflecting a 21% growth, showcasing the company's robust market performance and profitability.
- Strategic Acquisition Milestone: The acquisition of LymphaTech is viewed as a significant step in transitioning from a product-focused company to a comprehensive leader in lymphedema solutions, expected to accelerate disease identification and therapy access, thereby enhancing market competitiveness.
- Optimistic Future Outlook: Management projects 2026 revenue between $357 million and $365 million, representing an 8%-11% growth rate, despite facing short-term impacts from new Medicare authorization requirements, demonstrating confidence and adaptability in the market.
- Enhanced Operational Efficiency: The gross margin improved to 78.2% in Q4, attributed to lower manufacturing costs and stronger collections, with management emphasizing continued investments in technology and process optimization to support future growth.
See More
Tactile Systems Reports Strong 2025 Earnings Growth
- Significant Revenue Growth: Tactile Systems reported total revenue of $103.6 million in Q4 2025, reflecting a robust 21% increase that surpassed analyst expectations of $94 million, indicating strong performance in the medical device market.
- Profitability Improvement: The company's net income under GAAP rose by 9% to $10.6 million ($0.46 per share), showcasing sustained profitability and further bolstering investor confidence in the company's financial health.
- Strong Product Sales: Sales of airway clearance products surged by 66%, while sales and rentals of lymphedema treatment devices increased by 16%, demonstrating the effectiveness of the company's targeted strategies in niche markets.
- Optimistic Outlook: Management anticipates revenue growth of 8% to 11% in 2026, projecting figures between $357 million and $365 million, with non-GAAP EBITDA expected to range from $49 million to $51 million, highlighting the company's growth potential and market confidence moving forward.
See More
Wingstop Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Wingstop reported an adjusted EPS of $1.00 for Q4, surpassing analyst expectations of $0.84, indicating strong profitability and boosting market confidence in the company's future performance.
- Sales Miss: The quarterly sales of $175.694 million fell short of the analyst consensus estimate of $177.533 million, yet the overall performance reflects the company's resilience in a competitive fast-food market.
- Stock Surge: Following the earnings report, Wingstop's shares jumped 17.3% to $295.31 on Wednesday, signaling optimistic investor sentiment and potentially attracting more institutional interest in the stock.
- Positive Market Reaction: The broader U.S. stock market rose, with the Dow Jones index gaining around 250 points on Wednesday, and Wingstop's strong performance further fueled market optimism, reflecting investor confidence in the recovery of the restaurant sector.
See More
Wall Street Analysts Adjust Ratings on Key Stocks
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, reflecting varying market perspectives on these companies' futures, which could influence investor decisions and market trends.
- Upgrades and Downgrades: Specific rating changes include both upgrades and downgrades for certain stocks, which may lead to short-term volatility in the respective stocks, prompting investors to pay close attention.
- Market Reaction Expectations: Analyst rating adjustments typically trigger immediate market reactions, as investors may reassess their portfolios based on this information, thereby impacting overall market sentiment.
- Further Information Access: For a complete view of all analyst rating changes, including upgrades and downgrades, it is recommended to visit our analyst ratings page to stay updated on the latest market dynamics and professional insights.
See More
Tactile Systems Acquires LymphaTech to Strengthen Market Position
- Strategic Acquisition: Tactile Systems announced the acquisition of LymphaTech for $6.8 million in cash, aimed at enhancing its market position in the medical technology sector, particularly in improving disease identification and treatment options for lymphedema patients, which is expected to bolster the company's competitive edge in a rapidly growing market.
- Strong Financial Performance: Tactile Systems reported fourth-quarter earnings of 46 cents per share, exceeding the market expectation of 44 cents, with sales jumping 21% to $103.59 million, significantly surpassing Wall Street's estimate of $93.80 million, indicating robust demand for its lymphedema and airway clearance product lines.
- Optimistic 2026 Outlook: The company forecasts fiscal 2026 sales between $357 million and $365 million, exceeding the consensus of $347.94 million, while expecting adjusted EBITDA in the range of $49 million to $51 million, reflecting strong growth potential ahead.
- Strong Stock Performance: Tactile Systems shares rose 23.35% to $34.60 in premarket trading on Wednesday, reaching a new 52-week high, indicating a positive market reaction to the acquisition news, while technical analysis shows strong short-term upward momentum.
See More
Pitney Bowes Q4 Earnings Beat Expectations, Shares Surge
- Earnings Surprise: Pitney Bowes reported an adjusted EPS of 45 cents for Q4, surpassing the analyst consensus of 38 cents, indicating strong profitability and boosting investor confidence.
- Sales Miss: The quarterly sales of $478 million fell short of the expected $486.68 million, highlighting some market demand challenges that could impact future revenue growth.
- Stock Surge: The company's shares jumped 7.9% to $11.05 in pre-market trading, reflecting optimistic market sentiment regarding its future prospects and potentially attracting more investor interest.
- Positive Guidance: Pitney Bowes issued FY26 adjusted EPS guidance with a midpoint above estimates, further strengthening market confidence in its long-term growth potential.
See More
Tactile Systems Reports Strong Q4 2025 Earnings and Strategic Acquisition
- Strong Financial Performance: Tactile Systems reported total revenue of $329.5 million for 2025, a 12% year-over-year increase, with Q4 revenue reaching $103.6 million, reflecting a 21% growth, showcasing the company's robust market performance and profitability.
- Strategic Acquisition Milestone: The acquisition of LymphaTech is viewed as a significant step in transitioning from a product-focused company to a comprehensive leader in lymphedema solutions, expected to accelerate disease identification and therapy access, thereby enhancing market competitiveness.
- Optimistic Future Outlook: Management projects 2026 revenue between $357 million and $365 million, representing an 8%-11% growth rate, despite facing short-term impacts from new Medicare authorization requirements, demonstrating confidence and adaptability in the market.
- Enhanced Operational Efficiency: The gross margin improved to 78.2% in Q4, attributed to lower manufacturing costs and stronger collections, with management emphasizing continued investments in technology and process optimization to support future growth.
See More
